Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_3
2
40%
Ph phase_4
1
20%
Ph phase_2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

recruiting120%
withdrawn120%
completed360%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_2

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

NCT07407647
completedphase_4

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

NCT03568604
withdrawnphase_3

Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women

NCT03854396
completedphase_3

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349
completedphase_2

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

NCT00006219

Clinical Trials (5)

Showing 5 of 5 trials
NCT07407647Phase 2

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Recruiting
NCT03568604Phase 4

Changes to Vulva, Vestibule, Urethral Meatus and Vagina 20 Weeks Post Daily Prasterone in Women With Dyspareunia

Completed
NCT03854396Phase 3

Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women

Withdrawn
NCT01376349Phase 3

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Completed
NCT00006219Phase 2

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5